The short answer
Chromium may affect glucose control. Review the product before combining it with liraglutide; the exact added low-blood-sugar risk has not been measured.
What this answer covers
Supplemental chromium, with elemental amount and chemical form recorded.
- Supplement or preparation
- Chromium
- Medication ingredient
- liraglutide
What the human evidence shows
Chromium picolinate improved glucose-related measures in a study with glipizide, a different insulin-releasing drug. The broader chromium evidence is inconsistent and does not measure this exact pair’s hypoglycemia rate.
Why your treatment context matters
Liraglutide particularly increases low-blood-sugar risk when combined with insulin or insulin-releasing medicines. It should not be assumed to behave like those medicines by itself. The prescriber should consider the full regimen, meals and prior low readings before deciding whether additional monitoring is useful.
Check the supplement preparation
The Supplement Facts amount is elemental chromium. A high-dose picolinate study cannot define the effect of a routine multivitamin or every chromium form.
Keep the prescribed medicine plan
Confirm whether the prescription is VICTOZA for diabetes or SAXENDA for weight management. Their daily injection doses and indications differ. Report persistent vomiting, diarrhea or reduced eating, and do not alter the injection dose to compensate for a supplement.
Watch for low blood sugar
Follow your existing glucose-monitoring and low-blood-sugar treatment plan. New sweating, shakiness, hunger or confusion warrants a glucose check when possible. Severe confusion, a seizure or inability to swallow safely needs emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional glucose-monitoring concern follows from supplement glucose effects and the exact medicine context. This is not direct evidence of increased hypoglycemia or altered drug absorption.
- Exact scope
- Supplemental chromium, with elemental amount and chemical form recorded. with Exact liraglutide subcutaneous daily injection, diabetes and weight-management products distinguished. Exact RxNorm IN475968 liraglutide; subcutaneous daily injection, diabetes and weight-management products distinguished. Combination medicines are not assumed equivalent. VICTOZA and SAXENDA differ in indications and doses; neither is weekly dulaglutide.
- Medication form and route
- subcutaneous
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No exact pair human interaction trial identified. Preparation-specific positive and null results do not establish a universal effect, safe dose, spacing rule or drug concentration change.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline glucose and nutrient status.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed liraglutide.
Glucose-dependent GLP1 action, dose/indication-specific hypoglycemia, gastrointestinal effects and delayed gastric emptying.
How this applies: Exact RxNorm IN475968 liraglutide; subcutaneous daily injection, diabetes and weight-management products distinguished. Combination medicines are not assumed equivalent. VICTOZA and SAXENDA differ in indications and doses; neither is weekly dulaglutide.
No universal supplement dose, interval, event rate or untested formulation equivalence.
Source 2: official nutrient guidance
ods.od.nih.gov · Source check Sep 11, 2026
Population: People considering chromium supplements.
Glucose-control findings are inconsistent; chromium may add to effects of antidiabetes medicines and increase hypoglycemia risk.
How this applies: Only the named original drug, preparation, route and endpoint apply; no untested exact medication transfer.
General precaution, no exact liraglutide event rate; nutrient intake differs from high-dose picolinate trials.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: Adults with type 2 diabetes receiving glipizide GITS.
Insulin sensitivity and glycemic control improved.
How this applies: Only the named original drug, preparation, route and endpoint apply; no untested exact medication transfer.
Different insulin secretagogue and high-dose picolinate; no liraglutide levels or exact-pair hypoglycemia estimate.
Source 4: current product label
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: People prescribed SAXENDA for labeled weight management.
Hypoglycemia precautions depend on diabetes, age and concomitant insulin or secretagogues; gastrointestinal effects and delayed gastric emptying are described.
How this applies: Exact liraglutide weight-management formulation.
Not a vitamin absorption study or a weekly injection; VICTOZA has a different indication and dose.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. |
Article revision: acd1cb1ce2de0b39
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.